Antireflux surgery not better than medical therapy for reducing risk of esophageal adenocarcinoma in Barrett's esophagus

This multinational population-based cohort study investigated incident esophageal adenocarcinoma risk in patients with Barrett’s esophagus (N = 33,939) treated with antireflux surgery compared to those who did not undergo surgery but were treated with proton pump inhibitors. The patients were followed for 32 years. EAC risk was calculated using multivariable Cox regression, providing hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, sex, country, calendar year, and comorbidity.

In patients with Barrett’s esophagus, antireflux treatment is recommended to reduce EAC. Antireflux surgery counteracts gastroesophageal reflux of all types of carcinogenic gastric content. This reduces esophageal acid exposure to a greater extent than antireflux medication like proton pump inhibitors.

The key results of the study are:

• 33,939 patients had Barrett’s esophagus.
• 542 patients constituting 1.6%, had undergone antireflux surgery.
• During follow-up, there was no decrease in overall HR in those having undergone antireflux surgery than non-operated patients using antireflux medication but rather increased with adjusted HR of 1.9.
• With longer follow-ups, HRs did not decrease. Instead, there was an increase for each follow-up category, from 1.8 within 1-4 years of follow-up to 4.4 after 10-32 years of follow-up.

They said that compared to antireflux medication, patients with Barrett’s esophagus who undergo antireflux surgery do not have a lower risk of esophageal adenocarcinoma.

Reference:

Åkerström, J. H., Santoni, G., Von Euler Chelpin, M., Ness-Jensen, E., Kauppila, J. H., Holmberg, D., & Lagergren, J. (2023). Antireflux surgery versus antireflux medication and risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. https://doi.org/10.1053/j.gastro.2023.08.050